内科理论与实践 ›› 2022, Vol. 17 ›› Issue (06): 428-434.doi: 10.16138/j.1673-6087.2022.06.002
收稿日期:
2022-08-02
出版日期:
2022-12-30
发布日期:
2023-02-27
通讯作者:
蔡 循 E-mail: 基金资助:
LU Hao1,2, XI Huimin1, LI Lu1, CAI Xun1()
Received:
2022-08-02
Online:
2022-12-30
Published:
2023-02-27
摘要:
目的:研究低剂量索拉非尼与全反式维A酸(all-trans retinoic acid, ATRA)联合,对野生型Fms样酪氨酸激酶3(Fms like tyrosine kinase3, FLT3)的急性髓系白血病(acute myeloid leukemia, AML)细胞的效应及机制。方法:以野生型FLT3的AML细胞系HL-60、U937以及ATRA耐药的HL-60细胞系——HL-60Res为体外模型,以细胞表面分化抗原CD11b和形态学观察评估细胞分化;应用蛋白质印迹法研究Raf蛋白激酶、促分裂原活化的蛋白激酶(mitogenactivated protein kinase, MEK)和胞外信号调节激酶(extracellular signal-regulated kinase, ERK)的活化状态、PU.1、C/增强子结合蛋白(enhancer-binding protein, EBP)β和C/EBPε的蛋白含量。结果:低剂量(0.1~0.5 μmol/L)索拉非尼促进ATRA诱导HL-60、U937和HL-60Res 3株细胞系分化。两药联合活化Raf、MEK和ERK,并上调PU.1、C/EBPβ和C/EBPε的蛋白含量,MEK的特异性抑制剂曲美替尼可抑制两药诱导的细胞分化、MEK/ERK活化以及PU.1、C/EBPβ和C/EBPε的蛋白含量上调。结论:索拉非尼与ATRA联合,通过Raf/MEK/ERK通路上调PU.1、C/EBPβ和C/EBPε的蛋白含量,诱导野生型FLT3的AML细胞分化。
中图分类号:
卢昊, 奚会民, 李璐, 蔡循. 低剂量索拉非尼联合全反式维A酸诱导野生型Fms样酪氨酸激酶3的急性髓系白血病细胞分化[J]. 内科理论与实践, 2022, 17(06): 428-434.
LU Hao, XI Huimin, LI Lu, CAI Xun. Low-dose sorafenib combined with all-trans retinoic acid induces differentiation of acute myeloid leukemia cells with wild type Fms like tyrosine kinase 3[J]. Journal of Internal Medicine Concepts & Practice, 2022, 17(06): 428-434.
[1] |
Medinger M, Passweg JR. Acute myeloid leukaemia genomics[J]. Br J Haematol, 2017, 179(4): 530-542.
doi: 10.1111/bjh.14823 URL |
[2] |
Döhner H, Weisdorf DJ, Bloomfield CD. Acute myeloid leukemia[J]. N Engl J Med, 2015, 373(12): 1136-1152.
doi: 10.1056/NEJMra1406184 URL |
[3] | Ferrara F, Vitagliano O. Induction therapy in acute myeloid leukemia: is it time to put aside standard 3+7?[J]. Hematol Oncol, 2019, 37(5):558-563. |
[4] | Tallman MS. Differentiating therapy in acute myeloid leukemia[J]. Leukemia, 1996, 1010(8):1262-1268. |
[5] |
Gong L, Giacomini MM, Giacomini C, et al. PharmGKB summary: sorafenib pathways[J]. Pharmacogenet Genomics, 2017, 27(6): 240-246.
doi: 10.1097/FPC.0000000000000279 URL |
[6] |
Antar A, Otrock ZK, El-Cheikh J, et al. Inhibition of FLT3 in AML: a focus on sorafenib[J]. Bone Marrow Transplant, 2017, 52(3): 344-351.
doi: 10.1038/bmt.2016.251 URL |
[7] |
Mori S, Cortes J, Kantarjian H, et al. Potential role of sorafenib in the treatment of acute myeloid leukemia[J]. Leuk Lymphoma, 2008, 49(12): 2246-2255.
doi: 10.1080/10428190802510349 URL |
[8] |
Yalniz F, Abou Dalle I, Kantarjian H, et al. Prognostic significance of baseline FLT3-ITD mutant allele level in acute myeloid leukemia treated with intensive chemotherapy with/without sorafenib[J]. Am J Hematol, 2019, 94(9): 984-991.
doi: 10.1002/ajh.25553 pmid: 31237017 |
[9] |
Battipaglia G, Massoud R, Ahmed SO, et al. Efficacy and feasibility of sorafenib as a maintenance agent after allogeneic hematopoietic stem cell transplantation for Fms-like tyrosine kinase 3 mutated acute myeloid leukemia[J]. Clin Lymphoma Myeloma Leuk, 2019, 19(8): 506-508.
doi: S2152-2650(19)30109-0 pmid: 31122828 |
[10] |
Roolf C, Dybowski N, Sekora A, et al. Phosphoproteome analysis reveals differential mode of action of sorafenib in wildtype and mutated FLT3 acute myeloid leukemia (AML) cells[J]. Mol Cell Proteomics, 2017, 16(7): 1365-1376.
doi: 10.1074/mcp.M117.067462 pmid: 28450419 |
[11] |
Fouladi F, Jehn LB, Metzelder SK, et al. Sorafenib induces paradoxical phosphorylation of the extracellular signal-regulated kinase pathway in acute myeloid leukemia cells lacking FLT3-ITD mutation[J]. Leuk Lymphoma, 2015, 56(9): 2690-2698.
doi: 10.3109/10428194.2014.1003055 URL |
[12] |
Poulikakos PI, Zhang C, Bollag G, et al. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF[J]. Nature, 2010, 464(7287): 427-430.
doi: 10.1038/nature08902 URL |
[13] |
Miranda MB, Xu H, Torchia JA, et al. Cytokine-induced myeloid differentiation is dependent on activation of the MEK/ERK pathway[J]. Leuk Res, 2005, 29(11): 1293-306.
doi: 10.1016/j.leukres.2005.03.016 URL |
[14] |
Yen A, Roberson MS, Varvayanis S, et al. Retinoic acid induced mitogen-activated protein (MAP)/extracellular signal-regulated kinase (ERK) kinase-dependent MAP kinase activation needed to elicit HL-60 cell differentiation and growth arrest[J]. Cancer Res, 1998, 58(14): 3163-3172.
pmid: 9679985 |
[15] |
Wang R, Xia L, Gabrilove J, et al. Sorafenib inhibition of Mcl-1 accelerates ATRA-induced apoptosis in differentiation-responsive AML cells[J]. Clin Cancer Res, 2016, 22(5): 1211-1221.
doi: 10.1158/1078-0432.CCR-15-0663 pmid: 26459180 |
[16] |
Ma HS, Greenblatt SM, Shirley CM, et al. All-trans retinoic acid synergizes with FLT3 inhibition to eliminate FLT3/ITD+ leukemia stem cells in vitro and in vivo[J]. Blood, 2016, 127(23): 2867-2878.
doi: 10.1182/blood-2015-05-646786 URL |
[17] |
Röllig C, Serve H, Noppeney R, et al. Sorafenib or placebo in patients with newly diagnosed acute myeloid leukaemia: long-term follow-up of the randomized controlled SORAML trial[J]. Leukemia, 2021, 35(9): 2517-2525.
doi: 10.1038/s41375-021-01148-x pmid: 33603142 |
[18] |
Strumberg D, Richly H, Hilger RA, et al. Phase Ⅰ clinical and pharmacokinetic study of the novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors[J]. J Clin Oncol, 2005, 23(5): 965-972.
doi: 10.1200/JCO.2005.06.124 pmid: 15613696 |
[19] |
Miranda MB, Johnson DE. Signal transduction pathways that contribute to myeloid differentiation[J]. Leukemia, 2007, 21(7): 1363-1377.
doi: 10.1038/sj.leu.2404690 pmid: 17443228 |
[20] | Li ZY, Liang C, Ding M, et al. Enzastaurin enhances ATRA-induced differentiation of acute myeloid leukemia cells[J]. Am J Transl Res, 2020, 12(12): 7836-7854. |
[21] |
Lee S, Shuman JD, Guszczynski T, et al. RSK-mediated phosphorylation in the C/EBPβ leucine zipper regulates DNA binding, dimerization, and growth arrest activity[J]. Mol Cell Biol, 2010, 30(11): 2621-2635.
doi: 10.1128/MCB.00782-09 URL |
[22] |
Lu J, Wu DM, Zheng YL, et al. Troxerutin counteracts domoic acid-induced memory deficits in mice by inhibiting CCAAT/enhancer binding protein β-mediated inflammatory response and oxidative stress[J]. J Immunol, 2013, 190(7), 3466-3479.
doi: 10.4049/jimmunol.1202862 pmid: 23420885 |
[23] |
Murakami M, Ito H, Hagiwara K, et al. Sphingosine kinase 1/S1P pathway involvement in the GDNF-induced GAP43 transcription[J]. J Cell Biochem, 2011, 112(11): 3449-3458.
doi: 10.1002/jcb.23275 pmid: 21769916 |
[24] |
Yoshida H, Ichikawa H, Tagata Y, et al. PML-retinoic acid receptor alpha inhibits PML Ⅳ enhancement of PU.1-induced C/EBPepsilon expression in myeloid differentiation[J]. Mol Cell Biol, 2007, 27(16): 5819-5834.
doi: 10.1128/MCB.02422-06 URL |
[25] |
Mueller BU, Pabst T, Fos J, et al. ATRA resolves the differentiation block in t(15;17) acute myeloid leukemia by restoring PU.1 expression[J]. Blood, 2006, 107(8): 3330-3338.
doi: 10.1182/blood-2005-07-3068 pmid: 16352814 |
[1] | 蒋天依, 刘福佳, 程雯艳, 赵慧瑾, 沈杨. 重组人血小板生成素治疗急性髓系白血病化疗后血小板减少[J]. 内科理论与实践, 2022, 17(04): 283-288. |
[2] | 徐娜娜, 吴涛, 寇明坤, 白海. ASXL1基因突变在急性髓系白血病中的研究进展[J]. 内科理论与实践, 2022, 17(04): 353-355. |
[3] | 罗东凤, 游建华, 李啸扬, 李军民, 张赟翔. 不耐受强化化疗的初治老年急性髓系白血病患者诱导治疗疗效及安全性[J]. 内科理论与实践, 2022, 17(03): 220-226. |
[4] | 冯秀娟, 吴涛, 白海. 急性髓系白血病DNA异常甲基化及治疗进展[J]. 内科理论与实践, 2021, 16(04): 282-286. |
[5] | 黄磊, 叶晨静, 吴超, 徐文彬, 俞晴, 李军民, 阎骅. 阿扎胞苷联合venetoclax治疗新诊断老年急性髓系白血病的临床观察[J]. 内科理论与实践, 2021, 16(03): 178-182. |
[6] | 董悦昕, 李啸扬, 张赟翔, 李军民,. 恶性肿瘤继发急性髓系白血病的临床预后分析[J]. 内科理论与实践, 2019, 14(06): 361-365. |
[7] | 李雅, 陈瑜, 李军民,. 老年急性髓系白血病的治疗进展[J]. 内科理论与实践, 2019, 14(06): 391-394. |
[8] | 刘之茵, 陈钰, 陈玉宝, 严泽莹, 王莹, 李佳明, 孙海敏, 张苏江,. CLAG方案治疗复发、难治急性髓系白血病疗效、安全性分析及随访[J]. 内科理论与实践, 2019, 14(02): 116-120. |
[9] | 石晓东, 戴钰俊, 杨莹, 王盼盼, 王月英,. 西罗莫司靶向治疗DNA甲基转移酶3A突变的急性髓系白血病的研究[J]. 内科理论与实践, 2018, 13(03): 175-180. |
[10] | 李佳明, 张苏江, 严泽莹, 王莹, 刘之茵, 孙海敏, 陈玉宝, 陈钰,. 单药地西他滨比较沙利度胺联合全反式维A酸治疗1型骨髓增生异常综合征[J]. 内科理论与实践, 2018, 13(02): 98-102. |
[11] | 尹春荣, 高雯慧, 王紫薇, 王苓, 唐暐, 王建民, 胡炯,. 难治性急性髓系白血病异基因造血干细胞移植治疗疗效分析[J]. 内科理论与实践, 2018, 13(02): 76-80. |
[12] | 杨斌,陆余良,杨国正,朱凯龙. 一种基于虚拟力导向和细胞分化的免疫网络分类算法[J]. 上海交通大学学报(自然版), 2017, 51(1): 98-. |
[13] | 林怀安,余力,王健,张波,郑丹宁,周佳. 丹参对3T3-L1 细胞成脂分化与增殖的影响[J]. 组织工程与重建外科杂志, 2017, 13(1): 17-20. |
[14] | 胡伊, 陈云硕, 王盼盼, 程雯艳, 赵慧瑾, 沈杨,. 164例非M3型急性髓系白血病免疫表型的临床预后研究[J]. 内科理论与实践, 2017, 12(05): 344-350. |
[15] | 夏莉, 张伟娜, 王月英,. 高三尖杉酯碱联合尼洛替尼治疗M2b型急性髓系白血病[J]. 内科理论与实践, 2017, 12(04): 293-297. |
阅读次数 | ||||||
全文 |
|
|||||
摘要 |
|
|||||